MOA Life Plus Co. Ltd.

KOSDAQ:A142760 Stock Report

Market Cap: ₩45.7b

MOA Life Plus Past Earnings Performance

Past criteria checks 0/6

MOA Life Plus has been growing earnings at an average annual rate of 31.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 30.6% per year.

Key information

31.6%

Earnings growth rate

40.7%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-30.6%
Return on equity-15.1%
Net Margin-66.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Health Check: How Prudently Does MOA Life Plus (KOSDAQ:142760) Use Debt?

Oct 18
Health Check: How Prudently Does MOA Life Plus (KOSDAQ:142760) Use Debt?

There's No Escaping Bioleaders Corporation's (KOSDAQ:142760) Muted Revenues Despite A 30% Share Price Rise

Apr 19
There's No Escaping Bioleaders Corporation's (KOSDAQ:142760) Muted Revenues Despite A 30% Share Price Rise

Bioleaders Corporation's (KOSDAQ:142760) Business And Shares Still Trailing The Industry

Mar 01
Bioleaders Corporation's (KOSDAQ:142760) Business And Shares Still Trailing The Industry

Bioleaders' (KOSDAQ:142760) Shareholders Are Down 47% On Their Shares

Feb 16
Bioleaders' (KOSDAQ:142760) Shareholders Are Down 47% On Their Shares

Revenue & Expenses Breakdown

How MOA Life Plus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A142760 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417,080-11,2835,6751,015
30 Jun 2418,436-12,0137,1241,257
31 Mar 2418,548-8,9227,9771,600
31 Dec 2318,245-6,2047,9181,809
30 Sep 23-40,63610,742-6,0441,915
30 Jun 23-16,1109,543-9063,100
31 Mar 231,909-2054,8643,451
31 Dec 2222,004-2,46811,4703,856
30 Sep 22104,738-26,14834,1084,567
30 Jun 2299,393-21,28435,1204,007
31 Mar 22100,298-19,15934,3304,409
31 Dec 21101,170-19,76831,3894,481
30 Sep 2198,814-15,68828,7133,781
30 Jun 2192,955-23,18426,2844,133
31 Mar 2185,999-21,77825,5653,673
31 Dec 2080,453-21,13826,9113,419
30 Sep 2067,761-24,86233,1673,388
30 Jun 2066,300-22,32433,5332,996
31 Mar 2067,138-27,90034,2432,783
31 Dec 1972,877-28,04635,8412,645
30 Sep 1987,455-24,52529,6562,817
30 Jun 1998,845-23,27933,5592,464
31 Mar 19107,313-17,11135,7972,555
31 Dec 1886,067-17,22829,2522,552
30 Sep 1862,205-9,13722,2862,504
30 Jun 1834,764-8,11812,8712,670
31 Mar 1811,497-7,8295,0452,707
31 Dec 177,607-6,6474,2672,739
31 Dec 162,501-5,8963,4382,820

Quality Earnings: A142760 is currently unprofitable.

Growing Profit Margin: A142760 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A142760 is unprofitable, but has reduced losses over the past 5 years at a rate of 31.6% per year.

Accelerating Growth: Unable to compare A142760's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A142760 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A142760 has a negative Return on Equity (-15.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MOA Life Plus Co. Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution